
Keywords: Tardive dyskinesia (TD); Pharmacogenetics; Pathophysiology; Dopamine D2 receptor gene (DRD2); Dopamine D3 receptor gene (DRD3); Vesicular monoamine transporter 2 gene (VMAT2/SLC18A2); Heparan sulfate proteoglycan 2 (HSPG2); Manganese superoxide dismutase